Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
about
EZH2 in normal hematopoiesis and hematological malignanciesMYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical managementNoncoding RNA in oncogenesis: a new era of identifying key playersCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomac-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignanciesThe role of miR-29b in cancer: regulation, function, and signalingThe role of MIZ-1 in MYC-dependent tumorigenesisMicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tuneThe tumor microenvironment shapes hallmarks of mature B-cell malignancies.Epigenetics in Brain Tumors: HDACs Take Center StageKey nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancerReactive oxygen species contribute to arsenic-induced EZH2 phosphorylation in human bronchial epithelial cells and lung cancer cellsEpigenetically regulated miR-145 suppresses colon cancer invasion and metastasis by targeting LASP1.Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice.Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.MYC cofactors: molecular switches controlling diverse biological outcomes.EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumourigenesismiR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.EZH2 in normal and malignant hematopoiesis.Epigenetic alteration and microRNA dysregulation in cancerMir-29 repression in bladder outlet obstruction contributes to matrix remodeling and altered stiffness.Polycomb genes, miRNA, and their deregulation in B-cell malignanciesSOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cellsSmall molecules targeting c-Myc oncogene: promising anti-cancer therapeuticsEffects of PSCA rs2294008 (C/T) and c-MYC rs9642880 (G/T) polymorphisms on bladder cancer: evidence from a meta-analysis.Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2.c-Myc Represses Tumor-Suppressive microRNAs, let-7a, miR-16 and miR-29b, and Induces Cyclin D2-Mediated Cell Proliferation in Ewing's Sarcoma Cell LineBurkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation.HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.Cross disease analysis of co-functional microRNA pairs on a reconstructed network of disease-gene-microRNA tripartite.ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms.Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Mechanisms of epigenetic deregulation in lymphoid neoplasms.Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expressionRegulation of the DNA Methylation Landscape in Human Somatic Cell Reprogramming by the miR-29 Family.Non-coding RNAs and cancer.Feedback Loop Regulation of SCAP/SREBP-1 by miR-29 Modulates EGFR Signaling-Driven Glioblastoma Growth.A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
P2860
Q26779821-8FCAAE4C-13A3-4C59-A637-21F4710660DCQ26785379-0139763F-70E8-491A-AEAD-38E9A3B363F2Q26823718-7B40E832-E0F5-4520-9CFE-2B9826DE4359Q26851166-7669561A-8F28-4BCC-BBC8-0495FA8563E0Q26851373-B5C8940A-FA33-4670-BF22-6791E3905F08Q26851543-D83E6933-18B1-4701-BB4D-A58F7FAE8547Q27010254-CEA8B474-9218-4240-B410-C4B7AFADD7D5Q27013740-F0414FDD-1B52-42AD-9E9D-125BD06CFEDEQ27687567-1758EDE9-9C60-49DC-A1B5-CECB7E4A7D0CQ28080964-6F6A5654-43F8-4185-98A7-DBF5CE1C404AQ28082679-83B765AD-DBD9-433C-8978-B968C3902360Q28392050-38353D23-54A6-45CF-B3C2-D74CAAC158A3Q30008860-38EBD095-CB15-499F-AAC0-2EBA5602E1D9Q33586491-459E8E66-FBCF-4534-8D24-2F2BEA555A91Q33671971-CB6C9B03-4DBC-4D05-A54E-EBE59D7B543FQ33709960-EEC0018E-A44D-4F58-A442-5B968D830169Q34000446-DACD8D79-B130-4115-AA16-20225F833828Q34083178-1049C7C5-2B75-424E-85FD-96F1C939F905Q34199631-3528AC49-6D54-4BCD-9CA2-EB010AB9581FQ34283601-5E030870-818D-44D1-B6FF-41B12061C235Q34375614-A43C0CA4-7842-40FE-8E42-E871A5EF1D58Q34392645-868148FC-2C7F-4C20-9E73-6DFA8FE3585AQ35067766-E82A1F38-3DDB-491C-B605-465609C2E06DQ35103527-4B524D62-2CEC-4619-8004-C976765CC6BCQ35218210-9D3A9AB5-C599-4EEB-A0D0-3B98613801F2Q35353405-162DF332-0477-44C0-B5D1-B1CB874BA515Q35480048-9106E682-30A6-485F-AC68-E6255AD561A3Q35696142-323D8320-0F52-488F-AD03-B17D6B2A5D29Q35783276-FB43297D-7BFB-42CD-8659-E3D008A32914Q36143915-40E20FCC-150B-4CBD-B95F-96090C1A5656Q36296735-BB2DB0DE-F615-4572-923C-4FF36CA1CE00Q36322428-968123ED-B5EB-4B0A-8F36-12CD5056DADEQ36342882-080FFD19-45CC-4F31-9EAD-E6CFCCF6528FQ36445523-1ACDEE3A-A7BB-4CC3-991B-5C69402A8E34Q36873265-0054E88D-64EB-4F18-872F-1C2FA607EA30Q36956957-86412C8E-2164-4C15-A056-AD0E8E49ECC9Q37095868-AED777D0-1774-42DE-BBB6-1AF28ECE684CQ37139278-B75B2129-7621-4E31-978A-82BEDB9447F4Q37168356-C6191614-2C75-4076-AB4B-605B06154627Q37259187-F7B01C8D-ABD3-4B46-BBFA-C85C8455B88F
P2860
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@ast
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en-gb
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@nl
type
label
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@ast
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en-gb
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@nl
prefLabel
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@ast
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en-gb
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@nl
P2093
P2860
P3181
P1433
P1476
Coordinated silencing of MYC-m ...... in aggressive B-Cell lymphomas
@en
P2093
Eduardo Sotomayor
Edward Seto
Jianguo Tao
Jianhong Lin
John C Chan
Kapil Bhalla
Kenneth L Wright
Lynn C Moscinski
P2860
P304
P3181
P356
10.1016/J.CCR.2012.09.003
P407
P577
2012-10-16T00:00:00Z